Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb’s Liso-Cel meets key endpoints in blood cancer trial
Image: Bristol-Myers Squibb’s blood cancer treatment Liso-Cel has achieved primary and secondary endpoints in TRANSCEND NHL 001 study. Photo: courtesy of Rept0n1x.
Image: Bristol-Myers Squibb’s blood cancer treatment Liso-Cel has achieved primary and secondary endpoints in TRANSCEND NHL 001 study. Photo: courtesy of Rept0n1x.